Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low molecular weight heparin versus mechanical VTE prevention in hospitalized COVID-19 patients
ChiCTR2000030946Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of low molecular weight heparin calcium in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Biochemical indicators. Started Feb 2020; status: recruiting.
02
Drugs
low molecular weight heparin calcium
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000030946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030946.